bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2025.11.09.687017

Alternate VEGFA isoform expression in fibrosarcoma leads to plasticity in cellular migration and differences in sensitivity to inhibition with anti-VEGFA antibodies

Lee, Y.-C.·L Aguero Burgos, B.·Green, N. H.·Claeyssens, F.·English, W. R.
View original source ↗Export metadata ↓

Abstract

Metastasis remains a primary contributor to cancer-related mortality. Elevated expression of soluble vascular endothelial growth factor A (VEGFA) isoforms is linked to increased metastatic potential and enhanced cellular plasticity in response to microenvironmental changes. To investigate the connection between VEGFA isoform expression, migration plasticity, and metastasis, we analyzed the migratory behavior of fibrosarcoma cells expressing single VEGFA isoforms within engineered microenvironments mimicking tumor-associated extracellular matrix (ECM) architectures that drive distinct migration modes. Fibrosarcoma cell lines expressing VEGFA120 or VEGFA188 were derived from embryonic (Fs120 and Fs188) or mature skin fibroblasts, ensuring comparable VEGFA isoform expression across cells of different origins. Characterization of collagen fibril diameter and organization in tumors derived from Fs120 or Fs188 cells showed that Fs120 tumors had a higher degree of fibril alignment, suggesting VEGFA120 expression may facilitate ECM remodeling to support metastasis. To simulate these different collagen fibril structures for use in migration studies in vitro, we developed 3D platforms representing aligned and randomly organized collagen fibers using electrospinning of polycaprolactone. On 2D surfaces favoring mesenchymal migration and on 3D electrospun scaffolds promoting contact-guided migration, VEGFA120- and VEGFA188-expressing cells exhibited similar migratory capacities, regardless of their origin. However, anti-VEGFA antibodies selectively inhibited the migration of VEGFA120-expressing cells on fibronectin-coated surfaces and on aligned fiber scaffolds, but not non-aligned fibers, revealing isoform-specific sensitivity to VEGFA inhibition. In conclusion, while the expression of single VEGFA isoforms does not directly alter migration plasticity, VEGFA120 expression in mouse fibrosarcomas uniquely promotes ECM reorganization in tumors and cells expressing VEGF120 show increased sensitivity to anti-VEGFA antibodies.

Explore related subjects

cancer biologyPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Lee, Y.-C., L Aguero Burgos, B., Green, N. H., Claeyssens, F., English, W. R.. 2025-11-10. Alternate VEGFA isoform expression in fibrosarcoma leads to plasticity in cellular migration and differences in sensitivity to inhibition with anti-VEGFA antibodies. https://doi.org/10.1101/2025.11.09.687017

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

BAF complexes cooperate with lineage-restricted transcription factors to establish cell-state-specific regulatory programs

BRG1/BRM-associated factor (BAF) complexes are essential regulators of chromatin organization and cell identity. Genes encoding BAF subunits are among the most frequently mutated in human cancer. Yet, how disruption of a single subunit gives rise to distinct tumor states remains poorly understood. Atypical teratoid rhabdoid tumors (ATRTs) provide a compelling model, as they are uniformly driven by bi-allelic loss of the BAF subunit SMARCB1, yet segregate into distinct molecular subtypes. Using integrated multi-omics profiling of patient-derived ATRT organoids and primary tumor tissues, we show that transcriptional and chromatin accessibility changes upon SMARCB1 reconstitution are directed by subtype- and lineage-specific transcription factor (TF) repertoires. Genome-wide binding and transcriptomic analyses reveal that SMARCB1 reconstitution enables the lineage-specific TF RFX4 to engage regulatory elements and activate neuronal differentiation programs, partially reprogramming ATRT-MYC toward an ATRT-SHH-like identity. Together, these findings demonstrate that SMARCB1 loss disrupts TF-dependent chromatin priming, revealing that the lineage-specific regulatory output of BAF complexes is constrained by the underlying TF repertoire.

cancer biology↗
bioRxiv2026

Curvature-based schedule ordering is preserved in homogeneous and heterogeneous tumors

During treatment, dosing protocols with identical total dose may favor one schedule over another depending on how exposure is distributed over time. In homogeneous cell populations, Jensen's inequality has been shown to predict whether continuous or intermittent high-dose followed by low-dose is favored, based on the curvature of the concentration-effect function. Scheduling ordering can be performed based on curvature only: concave functions favor continuous dosing while convex functions favor intermittent dosing schedules with a high time-variance. However, tumors exhibit heterogeneous drug sensitivities, and treatment preferentially eliminates drug-sensitive cells, progressively shifting the surviving population toward greater drug resistance. Whether this treatment-induced selection can reverse curvature-based schedule ordering remains unclear. We develop a mathematical framework in which phenotypes share a common concentration-effect function but differ by fixed, nonnegative sensitivity scales. We prove that the ordering of equal-mean schedules is administrated solely by the scalar cumulative treatment effect, that is, by the curvature of the effect function alone. Consequently, baseline heterogeneity and treatment-induced selection can alter the magnitude of treatment response and the composition of surviving cells, but cannot reverse the ordering of equal-mean schedules predicted by the curvature of the single-cell concentration-effect function. This preservation holds across different temporal dosing profiles and repeated treatment cycles. Our work uncovers a general principle that curvature-based schedule ordering is preserved in heterogeneous tumors despite treatment-induced selection toward resistance.

cancer biology↗
bioRxiv2026

Enhanced antitumour activity of combined PD-1 blockade and HER2-targeted therapy is associated with reduced epithelial-mesenchymal transition and extracellular matrix-remodelling signatures in gastric cancer

Background The combination of PD-1 blockade, HER2-targeted therapy and chemotherapy improves outcomes in HER2-positive advanced gastric and gastro-oesophageal junction adenocarcinoma. However, chemotherapy can independently alter the tumour microenvironment, making the biological effects of PD-1 and HER2 targeting difficult to distinguish. We therefore investigated how PD-1 and HER2 blockade, alone and in combination, affect tumour growth and associated transcriptional programmes. Methods Immunodeficient NOG mice received human PBMCs by tail-vein injection. Three days later, NCI-N87 gastric cancer cells were implanted subcutaneously. Mice were randomised to vehicle, pembrolizumab, trastuzumab, or combination treatment. Tumour growth was assessed, and bulk RNA sequencing was used to identify treatment-associated changes in gene expression, pathway enrichment, and tumour, stromal, and immune cell-associated signatures. Results Combined treatment produced greater tumour growth control than either monotherapy. Trastuzumab-treated tumours showed enrichment of immune activation, epithelial-mesenchymal transition (EMT), and TGF{beta}-associated signatures, whereas pembrolizumab alone produced a limited transcriptional effect. Combination treatment was associated with reduced proliferation, EMT, and stromal-remodelling signatures, alongside increased cytotoxic immune-associated signatures. Expression of extracellular matrix-associated genes, including VCAN, SPARC, POSTN, collagen genes, and FAP, was lower in combination-treated tumours. Complement-related transcriptional pathways were also enriched. Conclusions In this chemotherapy-free model, combined PD-1 blockade and HER2-targeted therapy was associated with greater tumour growth control, enrichment of cytotoxic immune-associated transcriptional signatures, and reduced EMT and extracellular matrix remodelling signatures. These findings provide hypotheses for further mechanistic validation.

cancer biology↗